African swine fever virus cDNA and Antigen

ASFV is a highly contagious and often fatal viral disease that affects domestic and wild pigs. It is caused by the African swine fever virus, which is a large, double-stranded DNA virus with a complex structure. ASFV has many structural proteins, including:

ASFV genome is a circular, double-stranded DNA molecule that encodes the genetic information necessary for the virus to replicate and cause disease. The ASFV genome is approximately 170-230 kilobases in size, depending on the specific strain of the virus. It contains over 170 genes that encode viral proteins, including structural proteins, enzymes, and regulatory proteins, as well as non-coding regions known as intergenic regions. The genome of ASFV is relatively stable and have a low mutation rate. Study of ASFV genome can help to understand the mechanisms of viral replication, pathogenesis, and host-virus interaction, as well as providing valuable information for the development of diagnostic tools and vaccines.

Major capsid protein p72: This protein is the main component of the virus’s icosahedral capsid, which surrounds the viral DNA. It is essential for virus replication and assembly.

Structural protein p22: This protein is located within the virus particle and is involved in the formation of the virus’s core structure.

Envelope protein p54: This protein is a transmembrane protein that is located in the virus envelope. It is involved in virus entry into host cells and is a major target for the immune response.

Structural protein p49: This protein is located within the virus particle and is involved in the formation of the virus’s core structure.

Envelope protein 166: This protein is a transmembrane protein that is located in the virus envelope. It is involved in virus entry into host cells and is a major target for the immune response.

Envelope protein 167: This protein is a transmembrane protein that is located in the virus envelope. It is involved in virus entry into host cells and is a major target for the immune response.

Overall, the structural and envelope proteins of ASFV play critical roles in viral replication, evasion of the host immune response, and in the induction of protective immunity. Understanding the function of these key proteins is essential for the development of effective control measures against this devastating disease. Ongoing research efforts aim to identify new targets for antiviral drugs and to develop improved vaccines to protect pigs from ASFV infection.

 The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

ASFV cDNA and recombinant antigens can be used for a range of applications, including diagnosis and vaccine development. ASFV cDNA can be used to generate infectious ASFV particles, as well as to express specific antigens for use in ELISA and other immunoassays. Recombinant antigens can also be used to develop subunit vaccines, which are safer and easier to manufacture than traditional live-attenuated vaccines. Additionally, ASFV cDNA and recombinant antigens can be used to generate monoclonal antibodies for use in diagnostic tests.